Tyra Biosciences Inc
TYRA12.790USD
+0.640+5.27%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
680.86MMarket Cap
LossP/E TTM
More Details of Tyra Biosciences Inc Company
Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.
Company Info
Ticker SymbolTYRA
Company nameTyra Biosciences Inc
IPO dateSep 15, 2021
CEODr. Todd James Harris, Ph.D.
Number of employees60
Security typeOrdinary Share
Fiscal year-endSep 15
Address2656 State Street
CityCARLSBAD
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92008
Phone16197284760
Websitehttps://tyra.bio/
Ticker SymbolTYRA
IPO dateSep 15, 2021
CEODr. Todd James Harris, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Todd James Harris, Ph.D.
Dr. Todd James Harris, Ph.D.
President, Chief Executive Officer, Treasurer, Director
President, Chief Executive Officer, Treasurer, Director
1.36M
+0.09%
Mr. Daniel Bensen
Mr. Daniel Bensen
Chief Operating Officer
Chief Operating Officer
427.98K
--
Dr. Gilla Kaplan, Ph.D.
Dr. Gilla Kaplan, Ph.D.
Independent Director
Independent Director
28.23K
-68.50%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Chairman of the Board
Independent Chairman of the Board
24.43K
--
Dr. Susan M. Moran, M.D.
Dr. Susan M. Moran, M.D.
Independent Director
Independent Director
--
--
Mr. Alan Fuhrman, CPA
Mr. Alan Fuhrman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Rehan Verjee
Mr. Rehan Verjee
Independent Director
Independent Director
--
--
Dr. S. Michael Rothenberg, M.D., Ph.D.
Dr. S. Michael Rothenberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Douglas (Doug) Warner, M.D.
Dr. Douglas (Doug) Warner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Amy Conrad
Ms. Amy Conrad
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Todd James Harris, Ph.D.
Dr. Todd James Harris, Ph.D.
President, Chief Executive Officer, Treasurer, Director
President, Chief Executive Officer, Treasurer, Director
1.36M
+0.09%
Mr. Daniel Bensen
Mr. Daniel Bensen
Chief Operating Officer
Chief Operating Officer
427.98K
--
Dr. Gilla Kaplan, Ph.D.
Dr. Gilla Kaplan, Ph.D.
Independent Director
Independent Director
28.23K
-68.50%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Chairman of the Board
Independent Chairman of the Board
24.43K
--
Dr. Susan M. Moran, M.D.
Dr. Susan M. Moran, M.D.
Independent Director
Independent Director
--
--
Mr. Alan Fuhrman, CPA
Mr. Alan Fuhrman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
22.89%
Alta Partners
7.66%
Nextech Invest, Ltd.
7.61%
BVF Partners L.P.
7.40%
Canaan Partners
6.77%
Other
47.68%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
22.89%
Alta Partners
7.66%
Nextech Invest, Ltd.
7.61%
BVF Partners L.P.
7.40%
Canaan Partners
6.77%
Other
47.68%
Shareholder Types
Shareholders
Proportion
Venture Capital
39.14%
Hedge Fund
26.56%
Investment Advisor
21.21%
Investment Advisor/Hedge Fund
15.72%
Individual Investor
3.48%
Research Firm
1.97%
Private Equity
1.51%
Pension Fund
0.30%
Corporation
0.08%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
237
58.64M
110.28%
+1.26M
2025Q1
239
56.06M
105.46%
-647.87K
2024Q4
219
50.96M
100.70%
-3.70M
2024Q3
195
53.66M
101.74%
-3.04M
2024Q2
179
53.85M
102.74%
-1.82M
2024Q1
167
53.85M
102.76%
+5.34M
2023Q4
151
42.86M
99.62%
-3.01M
2023Q3
152
44.80M
104.35%
-3.44M
2023Q2
147
44.53M
104.65%
-3.27M
2023Q1
133
44.06M
103.88%
+915.22K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
12.20M
22.94%
+1.56M
+14.68%
Jun 16, 2025
Alta Partners
4.08M
7.67%
--
--
Mar 31, 2025
Nextech Invest, Ltd.
4.06M
7.63%
--
--
Mar 31, 2025
BVF Partners L.P.
3.94M
7.42%
--
--
Mar 31, 2025
Canaan Partners
4.14M
7.79%
-35.27K
-0.84%
Mar 31, 2025
Commodore Capital LP
2.75M
5.17%
+1.80M
+189.47%
May 07, 2025
TCG Crossover Management, LLC
2.90M
5.45%
--
--
Mar 31, 2025
Janus Henderson Investors
2.69M
5.06%
+946.92K
+54.22%
Mar 31, 2025
Vestal Point Capital, LP
2.88M
5.42%
+1.89M
+190.89%
Mar 31, 2025
Kynam Capital Management LP
2.41M
4.52%
+1.88M
+353.57%
Mar 31, 2025
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.25%
ALPS Medical Breakthroughs ETF
0.35%
JPMorgan Fundamental Data Science Small Core ETF
0.06%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.04%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.25%
ALPS Medical Breakthroughs ETF
Proportion0.35%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.06%
iShares Micro-Cap ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
